Related Experiment Video
Updated: Jun 18, 2026
06:38
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Update on novel agents in renal cell carcinoma
1Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263-0001, USA.
Expert Review of Anticancer Therapy
|December 4, 2009
Summary
This review details novel targeted therapies for advanced renal cell carcinoma (RCC). It highlights emerging treatments beyond current standards, focusing on new pathways to combat metastatic disease and overcome resistance.
Area of Science:
- Oncology
- Medical Research
Background:
- Renal cell carcinoma (RCC) presents with variable behavior, from indolent to aggressive with metastasis.
- Surgical resection is curative for early-stage RCC, but 40-50% of patients develop metastatic disease.
- Historically, cytokine therapy (IL-2, IFN-alpha) was used, with limited durable responses.
Purpose of the Study:
- To provide an updated overview of novel targeted agents in advanced clinical development for metastatic RCC.
- To discuss current research focusing on new pathways, drug resistance mechanisms, and novel therapeutic combinations.
Main Methods:
- Review of current literature on targeted therapies for metastatic RCC.
- Analysis of agents targeting pathways beyond VEGF.
- Examination of ongoing clinical investigations into novel combinations, sequences, and schedules.
Main Results:
- Vascular Endothelial Growth Factor (VEGF) pathway inhibitors (sunitinib, sorafenib, bevacizumab) are approved but often lead to disease stabilization with eventual progression.
- New targeted agents are being developed to address unmet needs in metastatic RCC.
- Research is actively exploring novel combinations and treatment schedules to improve outcomes.
Conclusions:
- Despite advances, metastatic RCC remains challenging, necessitating continuous development of novel therapeutic strategies.
- Targeting new pathways and understanding resistance mechanisms are crucial for improving patient outcomes.
- Ongoing clinical trials are vital for advancing the treatment landscape of advanced RCC.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:06Renal Drug Clearance: Overview
Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:15Renal Drug Excretion: Overview
As primary excretory organs, the kidneys maintain homeostasis by removing waste substances from the bloodstream. They comprise over a million units called nephrons, which serve as the kidney's functional units.
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules out...
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules out...